Over 90% of head and neck cancers overexpress the epidermal growth factor receptor
(EGFR). In diverse tumor types, EGFR overexpression has been associated with poorer …

Human papillomavirus (HPV)-related oropharyngeal squamous cell cancer (OPSCC) has
emerged as a distinct clinical entity of head and neck cancer with expected high survival …

Background The value of induction chemotherapy (ICT) remains under investigation despite
decades of research. New advancements in the field, specifically regarding the induction …

The mitogen-activating protein kinase (MAPK) pathway is central for cell proliferation,
differentiation, and senescence. In human, germline defects of the pathway contribute to …

Simple Summary Cancers in the head and neck region are often aggressive and poorly
respond to both irradiation or chemotherapy. Chemotherapy is currently limited by a small …

Background There is great interest in finding ways to identify patients who will develop
toxicity to cancer therapies. This has become especially pressing in the era of immune …

The epidermal growth factor receptor (EGFR) inhibitor cetuximab is the only FDA-approved
oncogene-targeting therapy for head and neck squamous cell carcinoma (HNSCC). Despite …

Purpose Radiotherapy plus cetuximab is an effective combination therapy for locally
advanced head and neck squamous cell carcinoma. The aim of our study was to determine …

Abstract The Epidermal Growth Factor Receptor (EGFR) has been targeted through the
development of selective tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAb) …

Germline single nucleotide polymorphisms are one of the most common genetic variations.
Polymorphisms that cause nonsynonymous mutations in gene coding regions are known to …